CN1489998A - Isosorbide dinitrate drops and preparation thereof - Google Patents
Isosorbide dinitrate drops and preparation thereof Download PDFInfo
- Publication number
- CN1489998A CN1489998A CNA031591175A CN03159117A CN1489998A CN 1489998 A CN1489998 A CN 1489998A CN A031591175 A CNA031591175 A CN A031591175A CN 03159117 A CN03159117 A CN 03159117A CN 1489998 A CN1489998 A CN 1489998A
- Authority
- CN
- China
- Prior art keywords
- isosorbide mononitrate
- coolant
- preparation
- mononitrate
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 13
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 title description 2
- 229960000201 isosorbide dinitrate Drugs 0.000 title 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 claims abstract description 34
- 229960003827 isosorbide mononitrate Drugs 0.000 claims abstract description 32
- 239000006187 pill Substances 0.000 claims abstract description 16
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 12
- 239000002826 coolant Substances 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 9
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 6
- 229940008099 dimethicone Drugs 0.000 claims description 6
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 6
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 6
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 6
- 229960000502 poloxamer Drugs 0.000 claims description 6
- 229920001983 poloxamer Polymers 0.000 claims description 6
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 claims description 2
- 239000001828 Gelatine Substances 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 229950009789 cetomacrogol 1000 Drugs 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229960005150 glycerol Drugs 0.000 claims description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 2
- -1 liquid paraffin Substances 0.000 claims description 2
- 229940057995 liquid paraffin Drugs 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 229940093430 polyethylene glycol 1500 Drugs 0.000 claims description 2
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 claims description 2
- 229940080350 sodium stearate Drugs 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
- 239000008158 vegetable oil Substances 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 2
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 description 19
- 238000000034 method Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 229940075507 glyceryl monostearate Drugs 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 208000019505 Deglutition disease Diseases 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000002464 muscle smooth vascular Anatomy 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical group OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010052337 Diastolic dysfunction Diseases 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitrogen oxide(NO) Natural products O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 235000013928 guanylic acid Nutrition 0.000 description 1
- 239000004226 guanylic acid Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000000304 vasodilatating effect Effects 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A dripping pill of isosorbide mononitrate is prepared through superfine pulverizing and conventional steps for preparing dripping pill. Its advantages are high disintegration speed, high stripping rate, quickly taking its effect, and low cost.
Description
Technical field
The present invention relates to a kind of pharmaceutical product and preparation method thereof, specifically drop pills of Isosorbide Mononitrate and preparation method thereof.
Background technology
Isosorbide mononitrate is the main bioactive metabolites of Dilatrate-SR, and is the same with other organic nitrates, and main pharmacological is loose vascular smooth muscle.Isosorbide mononitrate discharges nitrogen oxide (NO), and NO is identical with the endothelium relaxing factor, activates guanylate cyclase, cyclic guanylic acid (cGMP) in the smooth muscle cell is increased, thereby loose vascular smooth muscle makes peripheral arterial and venectasia, and is stronger to the venous dilating effect.Venectasia makes blood retention in periphery, and returned blood volume reduces, and press at diastole end in right ventricle's and pulmonary capillary wedge pressure PCWP presses (preload) to lower.Arteriectasia lowers peripheral vascular resistance, SAP and mean arterial pressure (afterload).Coronary artery expansion increases the coronary perfusion amount.Total effect is that myocardial oxygen consumption is reduced, and oxygen-supplying amount increases, and angina pectoris is alleviated.
Oral isosorbide mononitrate absorbs fully at gastrointestinal tract, no liver first-pass effect, and bioavailability is nearly 100%, and the serum-concentration peak time is being taken medicine back 30～60 minutes, and 6 hours action time, on average removing the half-life is 4-5 hour.The clearance rate of old people, liver function or renal function injury and diastolic dysfunction and healthy youngster indistinction.Isosorbide mononitrate forms Soquad (about 37%) and dextrorotation sorbitol (about 7%) behind the denitration base in serum, by discharging in the urine, 25% with the discharge of glucuronic acid form in addition, and 2% with the prototype discharge, discharges＜1% in the feces.The metabolite of isosorbide mononitrate does not all have vasodilative effect.The isosorbide mononitrate oral formulations of list marketing at present is tablet and capsule, is used for the long-term treatment of coronary heart disease clinically; Anginal prevention; Continue anginal treatment behind the myocardial infarction, with Folium Digitalis Purpureae or diuretic use in conjunction, the treatment chronic heart failure.
But isosorbide mononitrate sheet or capsule disintegration time length, dissolution and dissolution rate are lower, absorption difference, bioavailability is low, the supplementary product consumption ratio is big, child, old people, bed patient and dysphagia patients are taken inconvenience, compliance is poor, has influenced the performance of isosorbide mononitrate therapeutical effect.
The present invention makes the drop pills of Isosorbide Mononitrate agent by using ultramicro communication technique and dropping pill formulation Technology exactly, thereby overcomes isosorbide mononitrate sheet and capsular above defective, and the therapeutical effect of isosorbide mononitrate is given full play to.
Summary of the invention
The drop pills of Isosorbide Mononitrate of making by using ultramicro communication technique and dropping pill formulation Technology not only have disintegrate molten loose fast, dissolution and dissolution rate improve, steady quality, the pill volume is little, both can swallow also can buccal, easy to carry and use, onset is rapid, compliance is good, be particularly suitable for the child, the old people, the characteristics that bed patient and dysphagia patients are taken, but also have working condition and production equipment is simple, production cost is low, with tablet or capsule and compare the advantage that supplementary product consumption reduces, demonstrated fully the new drug research exploitation spirit that people-oriented.
For achieving the above object, the present invention by the following technical solutions: the isosorbide mononitrate fine powder of 1 weight portion through micronizing is added in 1～10 weight portion molten matrix, fully mixing, dropping preparation method is condensed into ball in coolant, remove coolant, drying, promptly.
The chemical name of the isosorbide mononitrate among the present invention is 1,4,3,6-two dehydration-D-Sorbitol-5-Mononitrate, and molecular formula is C
6H
9NO
6, molecular weight is 191.14, structural formula is
Substrate among the present invention includes but not limited to polyethylene glycol 6000, Macrogol 4000, polyethylene glycol 1500, cetomacrogol 1000, sodium stearate, glycerin gelatine, poloxamer, stearic acid, glycerol monostearate acid, insect wax etc.
Coolant among the present invention includes but not limited to dimethicone, liquid paraffin, vegetable oil, water, alcoholic solution etc.
Below through detecting to beneficial effect of the present invention as directed
One, detects index and method
1. disintegrate (molten loosing) time limit: check according to inspection technique disintegration (two appendix XA of Chinese Pharmacopoeia version in 2000).
2. dissolution rate: sample thief according to dissolution method (two appendix XC second methods of Chinese Pharmacopoeia version in 2000), is a solvent with water 500ml, rotating speed is that per minute 50 changes, and operation in accordance with the law is in the time of 5,10,20,30 and 45 minutes, get solution 10ml, filter, get subsequent filtrate as need testing solution.It is an amount of that other gets isosorbide mononitrate reference substance (put in the phosphorus pentoxide desiccator drying under reduced pressure to constant weight), be dissolved in water and quantitatively dilution make the solution that contains 40 μ g among every 1ml approximately, product solution in contrast.Get above-mentioned two kinds of solution,, measure trap respectively, calculate stripping quantity at the wavelength place of 214nm according to spectrophotography (two appendix IVA of Chinese Pharmacopoeia version in 2000).
Two, commercially available isosorbide mononitrate sheet testing result
1. disintegration time: 36 minutes
2. dissolution rate:
Time (minute) 5 10 20 30 45
Dissolution (%) 24.5 39.2 53.4 74.5 83.6
Three, example 1 sample detection result
1. the molten diffusing time: 3 minutes
2. dissolution rate:
Time (minute) 5 10 20 30 45
Dissolution (%) 64.5 88.6 98.7 99.2 99.4
Four, example 2 sample detection results
1. the molten diffusing time: 4 minutes
2. dissolution rate:
Time (minute) 5 10 20 30 45
Dissolution (%) 63.5 85.4 99.5 99.7 98.6
Five, example 3 sample detection results
1. the molten diffusing time: 7 minutes
2. dissolution rate:
Time (minute) 5 10 20 30 45
Dissolution (%) 59.3 84.2 98.6 100.4 99.2
Six, example 4 sample detection results
1. the molten diffusing time: 9 minutes
2. dissolution rate:
Time (minute) 5 10 20 30 45
Dissolution (%) 51.3 79.6 94.5 98.7 99.0
Seven, example 5 sample detection results
1. the molten diffusing time: 10 minutes
2. dissolution rate:
Time (minute) 5 10 20 30 45
Dissolution (%) 50.3 72.5 92.3 98.4 99.2
Eight, example 6 sample detection results
1. the molten diffusing time: 13 minutes
2. dissolution rate
Time (minute) 5 10 20 30 45
Dissolution (%) 49.6 71.5 86.7 98.2 99.4
The specific embodiment
One, example 1
Prescription:
Isosorbide mononitrate 5g
Polyethylene glycol 6000 15g
Make 1000
Method for making: the isosorbide mononitrate fine powder that the micronizing of learning from else's experience is crossed 200 mesh sieves is added in the fused polyethylene glycol 6000 substrate, stirs evenly, and with the dimethicone coolant, the dropping preparation method pill, drying, promptly.
Two, example 2
Prescription:
Isosorbide mononitrate 5g
Macrogol 4000 15g
Make 1000
Method for making: the isosorbide mononitrate fine powder that the micronizing of learning from else's experience is crossed 200 mesh sieves is added in the fused Macrogol 4000 substrate, stirs evenly, and with the dimethicone coolant, the dropping preparation method pill, drying, promptly.
Three, example 3
Prescription:
Isosorbide mononitrate 5g
Polyethylene glycol 6000 5g
Macrogol 4000 10g
Make 1000
Method for making: the isosorbide mononitrate fine powder that the micronizing of learning from else's experience is crossed 200 mesh sieves is added in fused Macrogol 4000 and the polyethylene glycol 6000 mixed-matrix, stirs evenly, and with the dimethicone coolant, the dropping preparation method pill, drying, promptly.
Four, example 4
Prescription:
Isosorbide mononitrate 5g
Glyceryl monostearate 15g
Make 1000
Method for making: the isosorbide mononitrate fine powder that the micronizing of learning from else's experience is crossed 200 mesh sieves is added in the fused glyceryl monostearate substrate, and mixing is a coolant with the frozen water, the dropping preparation method pill, and drying, promptly.
Five, example 5
Prescription:
Isosorbide mononitrate 5g
Polyethylene glycol 6000 10g
Poloxamer 5g
Make 1000
Method for making: the isosorbide mononitrate fine powder that the micronizing of learning from else's experience is crossed 200 mesh sieves is added in fused polyethylene glycol 6000 and the poloxamer mixed-matrix, stirs evenly, and with the dimethicone coolant, the dropping preparation method pill, drying, promptly.
Six, example 6
Prescription:
Isosorbide mononitrate 5g
Glyceryl monostearate 15g
Poloxamer 1g
Make 1000
Method for making: get the mixing fine powders that isosorbide mononitrate and poloxamer cross 200 mesh sieves through micronizing and be added in the fused glyceryl monostearate substrate, mixing is a coolant with the frozen water, the dropping preparation method pill, and drying, promptly.
Claims (4)
1. drop pills of Isosorbide Mononitrate and preparation method thereof is characterized in that: the isosorbide mononitrate fine powder of 1 weight portion through micronizing is added in 1～10 weight portion molten matrix, fully mixing, dropping preparation method is condensed into ball in coolant, remove coolant, drying, promptly.
The described isosorbide mononitrate of claim 1 chemical name be 1,4,3,6-two dehydration-D-Sorbitol-5-Mononitrate, molecular formula is C
9H
9NO
6, molecular weight is 191.14, structural formula is
3. the described substrate of claim 1 includes but not limited to polyethylene glycol 6000, Macrogol 4000, polyethylene glycol 1500, cetomacrogol 1000, sodium stearate, glycerin gelatine, poloxamer, stearic acid, glycerol monostearate acid, insect wax etc.
4. the described coolant of claim 1 includes but not limited to dimethicone, liquid paraffin, vegetable oil, water, alcoholic solution etc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031591175A CN1489998A (en) | 2003-09-08 | 2003-09-08 | Isosorbide dinitrate drops and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA031591175A CN1489998A (en) | 2003-09-08 | 2003-09-08 | Isosorbide dinitrate drops and preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1489998A true CN1489998A (en) | 2004-04-21 |
Family
ID=34157049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA031591175A Pending CN1489998A (en) | 2003-09-08 | 2003-09-08 | Isosorbide dinitrate drops and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1489998A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1872042B (en) * | 2005-06-01 | 2010-05-12 | 天津天士力制药股份有限公司 | Drop pills of Isosorbide Mononitrate, and preparation method |
-
2003
- 2003-09-08 CN CNA031591175A patent/CN1489998A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1872042B (en) * | 2005-06-01 | 2010-05-12 | 天津天士力制药股份有限公司 | Drop pills of Isosorbide Mononitrate, and preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1489998A (en) | Isosorbide dinitrate drops and preparation thereof | |
| CN1493298A (en) | Ginseng stem leaf total saponin drip pill and its preparation method | |
| CN1490000A (en) | Hippophae rhamnoide flavone drops and preparation thereof | |
| CN1528298A (en) | Isocarboxazid drop pill and preparing method thereof | |
| CN1528321A (en) | Rhizoma gastrodiae extract drop pill and preparing method thereof | |
| CN1528287A (en) | Herba lysionoti extract drop pill and preparing method thereof | |
| CN1528281A (en) | Rhododeudron molle toxin drop pill and preparing method thereof | |
| CN1602848A (en) | Ambroxol hydrochloride drop pills and its preparation method | |
| CN1526393A (en) | Hydralazine hydrochloride guttate pills and the prepn | |
| CN1562001A (en) | Carbazochrome sodium sulfoate dripping pill and its preparing method | |
| CN1546022A (en) | Dripping pills of luteanine hydrochloride and its preparation | |
| CN1528286A (en) | Soybean aglycone drop pill and preparing method thereof | |
| CN1528294A (en) | Indolol drop pill and preparing method thereof | |
| CN1602846A (en) | Oxyfenamate hydrochloride drop pills and its preparation method | |
| CN1493280A (en) | Mezereum drip pill and its preparation method | |
| CN1493290A (en) | Ferulaic acid piperazine drip pill and its preparation method | |
| CN1602845A (en) | Fenfluramine hydrochloride drop pills and its preparation method | |
| CN1602868A (en) | Dripping pills of ketotifen fumarate and its preparation method | |
| CN1493276A (en) | Ferulaic acid sodium drip pill and its preparation method | |
| CN1528318A (en) | Herba adonidis aglycone drop pill and preparing method thereof | |
| CN1582908A (en) | Tramadol hydrochloride drops and their preparation | |
| CN1562026A (en) | Cyclizine hydrochloride dripping pill and its preparing method | |
| CN1543935A (en) | Tulobuterol hydrochloride guttate pill and method for preparing the same | |
| CN1602860A (en) | Dripping pills of clemastine fumarate and its preparation method | |
| CN1528301A (en) | Nicorandic drop pill and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |